# Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

> **NCT02333045** · NA · TERMINATED · sponsor: **Emory University** · enrollment: 4 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Truvada qd
- **DRUG:** Maraviroc 300 qd

## Key facts

- **NCT ID:** NCT02333045
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2016-10-28
- **Final completion:** 2016-10-28
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.
- **Last updated:** 2018-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333045, "Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02333045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*